FDA Rejects MDMA-Assisted PTSD Therapy [Psychiatrist.com]
Wednesday, August 14, 2024 1 min read
Key Takeaway: The FDA has rejected the MDMA-assisted therapy for PTSD developed by Enveric Biosciences. CEO Joseph Tucker highlighted significant challenges in the study, particularly related to expectation bias and the delivery of psychological therapy. These issues complicate the treatment, especially given the nature of therapies that involve hallucinations. Future therapies may focus on non-hallucinogenic alternatives.
Price reaction · baseline $95.706 (2024-08-13 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
-7.8%
day 1 · peak
-9.2%
day 3
-5.2%
Market Sentiment Analysis
CONCERNS & RISKS
FDA rejected MDMA-assisted therapy for PTSD.
Study faced challenges related to expectation bias.
Delivery of psychological therapy was problematic.
Concerns about hallucinations in treatment protocol.
Full Press Release Details
Joseph Tucker, CEO and director at Enveric Biosciences, a biotech firm, suggested a pair of obstacles this study simply couldn’t overcome. “The thematic challenges that came to light in the Lykos [trial] largely focused around two elements: expectation bias and the delivery of the psychological therapy,” Tucker argued. “These are difficult to separate from any therapy that induces hallucinations and/or requires psychotherapy in the treatment protocol but would likely be eliminated as concerns for the impending next generation of non-hallucinogenic neuroplastogens.”
Full Article >>
Frequently Asked Questions
What therapy did the FDA reject?
The FDA rejected the MDMA-assisted therapy for PTSD developed by Enveric Biosciences.
What were the main challenges in the study?
The study faced challenges related to expectation bias and therapy delivery.
Who is the CEO of Enveric Biosciences?
Joseph Tucker is the CEO and director at Enveric Biosciences.
What future therapies might be considered?
Future therapies may focus on non-hallucinogenic neuroplastogens.